SKF 38393 and SCH 23390 Inhibit Reuptake of Serotonin by Rat Hypothalamic Synaptosomes

Abstract

Background/Aims: Both the dopamine receptor D₁ agonist SKF 38393 and the antagonist SCH 23390 are benzazepine derivatives that have been widely used as pharmacological tools and radioligands. Evidence suggests that behavioral effects of both compounds do not always correspond to their established receptor subtype selectivity. Here, we assessed the effects of SKF 38393 and SCH 23390 on the synaptosomal uptake of tritiated serotonin. Methods: Uptake experiments were performed by using [³H]serotonin and synaptosomal fractions prepared from the hypothalamus of rat brain. Results: Both SKF 38393 and SCH 23390 inhibited synaptosomal uptake of [³H]serotonin, with IC₅₀ values of 910 ± 60 nmol/l and 1,400 ± 80 nmol/l, respectively. Clomipramine, a known inhibitor of serotonin uptake, and (+)-amphetamine, a weak inhibitor, had IC₅₀ values of 14 ± 1 nmol/l and more than 10,000 nmol/l, respectively, under the same experimental conditions. The IC₅₀ values for SKF 38393 and SCH 23390 fall within the broad range of corresponding values for antidepressants that have been shown to inhibit the uptake of serotonin. This finding indicates that SKF 38393 and SCH 23390 can enhance the activity of the serotonergic system in the brain, a mechanism that may be responsible for some of the effects of these drugs. Conclusion: SKF 38393 and SCH 23390 are useful tools to differentiate D₁ from D₂ receptors, but their indirect effects on serotonergic mechanisms have to be considered.